Panitumumab-IRDye800 for fluorescence-guidance based metastatic lymph node
identification in patients with head and neck cancer  (Conference Presentation)

Nynke van den Berg; Nutte Teraphongphom; Willemieke S. F. J. Tummers; Steven Hong M.D.; Guolan Lu; Adam J. Gomez M.D.; Brock Martin M.D.; Robert Ertsey; Nicholas J. Oberhelman; Christina S Kong M.D.; Dimitros Colevas M.D.; Eben L. Rosenthal M.D.

doi:10.1117/12.2291298

Translator Disclaimer

14 March 2018 Panitumumab-IRDye800 for fluorescence-guidance based metastatic lymph node identification in patients with head and neck cancer (Conference Presentation)

Nynke van den Berg, Nutte Teraphongphom, Willemieke S. F. J. Tummers, Steven Hong M.D., Guolan Lu, Adam J. Gomez M.D., Brock Martin M.D., Robert Ertsey, Nicholas J. Oberhelman, Christina S Kong M.D., Dimitros Colevas M.D., Eben L. Rosenthal M.D.

Author Affiliations +

Proceedings Volume 10478, Molecular-Guided Surgery: Molecules, Devices, and Applications IV; 104780T (2018) https://doi.org/10.1117/12.2291298
Event: SPIE BiOS, 2018, San Francisco, California, United States

Abstract

BACKGROUND: Presence of lymph node (LN) metastasis is considered the most important prognostic factor in patients with head and neck cancer, yet intraoperative identification of metastatic LNs is considered challenging. We propose the near-infrared fluorescently labeled epidermal growth factor receptor (EGFR) antibody panitumumab-IRDye800 for intraoperative metastatic LN identification. METHODS: Patients were injected 2-5 days before surgery with panitumumab-IRDye800 (0.5 or 1.0 mg/kg). On the day of surgery, (excised) LN samples were evaluated on high sensitivity fluorescence imaging systems (SurgVision (SurgOptix), PINPOINT (Novadaq), and Pearl imager and Odyssey CLx (LI-COR Biosciences). Location and intensity of the fluorescence signal was correlated to the location of tumor as defined on the hematoxylin and eosin staining by the pathologist, and the EGFR expression pattern. We calculated the sensitivity, specificity, positive and negative predictive values of panitumumab-IRdye800 for metastatic LN identification. RESULTS: We thus far included 9/27 patients in our ongoing phase I trial. 244 LNs were removed intraoperatively of which 8 were tumor-positive. Fluorescence imaging of panitumumab-IRdye800 revealed 236 true-negative nodes (not fluorescent, not tumor-positive), 8 true-positive nodes (fluorescent, tumor-positive), 0 false-positive nodes (fluorescent, not tumor-positive) and 0 false-negative nodes (not fluorescent, tumor-positive) resulting in a sensitivity of 100%, a specificity of 100%, and a positive and negative predictive value of 100% and 100%, respectively. CONCLUSION: Preliminary results from our ongoing study suggest panitumumab-IRDye800 can identify metastatic LNs. Upon trial progression, if findings remain constant, it can open a whole new era for intraoperative metastatic LN identification.

Conference Presentation

Citation Download Citation

Nynke van den Berg, Nutte Teraphongphom, Willemieke S. F. J. Tummers, Steven Hong M.D., Guolan Lu, Adam J. Gomez M.D., Brock Martin M.D., Robert Ertsey, Nicholas J. Oberhelman, Christina S Kong M.D., Dimitros Colevas M.D., and Eben L. Rosenthal M.D. "Panitumumab-IRDye800 for fluorescence-guidance based metastatic lymph node identification in patients with head and neck cancer (Conference Presentation)", Proc. SPIE 10478, Molecular-Guided Surgery: Molecules, Devices, and Applications IV, 104780T (14 March 2018); https://doi.org/10.1117/12.2291298

ACCESS THE FULL ARTICLE